The UK Medicines and Healthcare products Regulatory Agency (MHRA) warned that inadequate electronic health record systems are costing hospitals eligibility for clinical trials. The regulator said noncompliant eHR systems could affect site selection by commercial sponsors and can undermine the ability to reconstruct trial data for marketing authorization applications and publications. MHRA’s guidance clarifies expectations for GCP-aligned eHR deployments, including audit trails and oversight requirements for investigators. The agency also raised concerns that weak data retention and collection capabilities may reduce patient recruitment and access to late-stage research. For biopharma, the warning shifts practical attention from scientific inclusion criteria to data integrity and systems compliance—factors that can directly influence timelines and trial recruitment efficiency.